Alvelestat (MPH966) for the Treatment of Alpha-1 Antitrypsin Deficiency (ATALANTa): A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of Alvelestat in Alpha-1 Antitrypsin Deficiency

Authors
Category Primary study
JournalAmerican Journal of Respiratory and Critical Care Medicine
Year 2024
This article has no abstract
Epistemonikos ID: b0ef13b5a9582045184ff78bd53957abe1dbd06a
First added on: Feb 17, 2025